Working with its clients to ensure a successful outcome in terms of market access, Grove Russian consultants provide expert advice in three key areas:
Recognizing that improved regulation will positively drive development within the Russian healthcare sector, the regulatory authorities have worked hard to develop and introduce an appropriate regulatory framework. Within this, the Federal Drug Reimbursement Program now provides free access to over 250 pharmaceutical products for the most vulnerable in the Russian society.
With the market split between OTC and prescription pharmaceutical products, an Essential Drug List is maintained by the authorities, and pricing (maximum sale price/mark up) is strictly controlled. For all other products, suppliers are responsible for their own price setting.
As a member of the Eurasian Economic Union, there has been some regulatory harmonization across the countries involved. The reality is however, that the implementation of any regulatory issues pertinent to the healthcare market will take some time to take effect.
As in other areas, the Ministry of Healthcare of the Russian Federation (MINZDRAV) plays a key role in pricing and reimbursement procedures.
The relatively transparent local regulatory environment requires careful navigation given its complexity. Only with an understanding of the reimbursement policies in Russia, can new market entrants hope to get their own reimbursement strategies and subsequent reimbursement submissions right. With experienced local consultants, Grove can assist with: